Statement: Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group.
Primary_evidence: Outcome Measurement:    Progression-Free Survival (PFS)   PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4.   Time frame: Baseline up to Month 33 Results 1:    Arm/Group Title: Docetaxel + Sunitinib   Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib).   Overall Number of Participants Analyzed: 296   Median (95% Confidence Interval)   Unit of Measure: months  Independent radiology assessment: 8.6        (8.2 to 10.3)   Investigator's assessment: 8.2        (7.3 to 8.6) Results 2:    Arm/Group Title: Docetaxel   Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks   Overall Number of Participants Analyzed: 297   Median (95% Confidence Interval)   Unit of Measure: months  Independent radiology assessment: 8.3        (7.7 to 9.6)   Investigator's assessment: 6.9        (6.5 to 7.3)